Where I see patients (3)
Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend?
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
British journal of cancer
ATM-SPARK: A GFP phase separation-based activity reporter of ATM.
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mut...
Time to breast cancer (invasive or DCIS) will be compared between the two treatment arms using a stratified Cox proportional hazards regression model.
Pilot Study of Pancreatic Cancer Screening
Proportion of participants with an abnormal MRI finding will be reported as an event. An estimated event rate of 19% in participants with a strong family history (FH) of pancreatic cancer and 10% in those participants without a st...
Combination Therapy in Cancers With Mutations in DNA Repair Genes
The percentage of participants with treatment-emergent adverse events as classified and graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5 will be reported
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Adv...
Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline
A Study of SGN-STNV in Advanced Solid Tumors
To be summarized using descriptive statistics
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous R...
ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed...
Study to Evaluate D-1553 in Subjects With Solid Tumors
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combinat...
Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK ...
Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)